What Is Valley Fever Symptoms? The Complete Guide

Valley fever is a fungal lung infection caused by inhaling Coccidioides spores from desert soil in the southwestern United States. The most common symptoms include fever (100-104°F), dry cough, chest pain, fatigue, and night sweats, appearing 1-3 weeks after exposure. While approximately 60% of infected people experience mild flu-like symptoms, 40% remain asymptomatic. Severe cases can spread beyond the lungs, requiring antifungal medication. This guide covers valley fever symptoms, diagnosis, treatment, and prevention using the latest 2025-2026 medical data.

Last updated: February 2026 — Updated with 2025 CDC surveillance data, IDSA treatment guidelines, and new diagnostic protocols from the University of Arizona College of Medicine.

What Is Valley Fever and What Are Its Primary Symptoms?

Valley fever, medically known as coccidioidomycosis, is a fungal infection caused by inhaling airborne spores of Coccidioides immitis or Coccidioides posadasii, fungi that live in desert soil across the southwestern United States. The primary symptoms include fever (often 100-104°F), dry cough, chest pain that worsens with deep breathing, fatigue, headache, muscle aches, and joint pain. According to the Centers for Disease Control and Prevention’s 2025 surveillance report, approximately 60% of infected individuals experience mild to moderate flu-like symptoms, while 40% remain asymptomatic. The infection mimics community-acquired pneumonia and is frequently misdiagnosed as bacterial pneumonia or influenza. The Arizona Department of Health Services’ 2025 annual report corroborates these findings, noting that valley fever accounts for 15-20% of community-acquired pneumonia cases in endemic areas.

How Do Valley Fever Symptoms Compare to Flu and COVID-19 Symptoms?

Symptom	Valley Fever	Influenza	COVID-19 (2025 variants)
Fever	Common (100-104°F)	Common (100-104°F)	Common (100-103°F)
Cough	Dry, persistent	Dry or productive	Dry, often with sore throat
Chest pain	Common, pleuritic	Uncommon	Uncommon
Fatigue	Severe, weeks to months	Moderate, 1-2 weeks	Moderate, 1-3 weeks
Rash	Red, painful nodules on legs	Rare	Rare
Joint pain	Common, especially knees	Common	Common
Night sweats	Common	Uncommon	Uncommon
Shortness of breath	Common in severe cases	Rare	Common
Onset after exposure	1-3 weeks	1-4 days	2-14 days
Duration	Weeks to months	1-2 weeks	1-3 weeks

According to the Arizona Department of Health Services’ 2025 annual report, valley fever is misdiagnosed as influenza or COVID-19 in approximately 30% of initial medical visits in endemic areas. The key distinguishing feature is symptom duration: valley fever symptoms persist beyond 3 weeks, while influenza typically resolves within 2 weeks. The Infectious Diseases Society of America’s 2025 clinical practice guidelines recommend valley fever testing for any patient in endemic areas with pneumonia-like symptoms lasting more than 10 days without improvement. The Mayo Clinic’s 2025 clinical review adds that the presence of night sweats and erythema nodosum rash strongly suggests valley fever over viral respiratory infections.

What Are the Early Symptoms of Valley Fever to Watch For?

Early valley fever symptoms appear 1-3 weeks after inhaling fungal spores and include fever reaching 100-104°F, a dry hacking cough, fatigue described by patients as “bone-deep exhaustion,” chest pain that worsens with deep breathing or coughing, and night sweats that soak through clothing. According to the University of Arizona College of Medicine’s 2025 valley fever cohort study, 75% of patients report the initial symptom as fever with cough, while 15% first notice the characteristic rash—tender red nodules on the shins called erythema nodosum. The Mayo Clinic’s 2025 clinical review notes that early symptoms are indistinguishable from other respiratory infections, making geographic exposure history the most important diagnostic clue. The CDC’s 2025 surveillance data confirms that patients who report recent travel to Arizona, California’s Central Valley, or New Mexico have a 10-fold higher probability of valley fever compared to those without such exposure.

What Are the Severe and Chronic Valley Fever Symptoms?

Severe valley fever occurs when the infection spreads beyond the lungs, a condition called disseminated coccidioidomycosis. According to the CDC’s 2025 Morbidity and Mortality Weekly Report, approximately 5-10% of symptomatic cases progress to severe disease. Symptoms of disseminated infection include meningitis (headache, neck stiffness, sensitivity to light), bone lesions causing localized pain and swelling, skin abscesses or ulcers, and joint inflammation. Chronic pulmonary valley fever develops in about 5% of cases and presents with persistent cough producing blood-tinged sputum, low-grade fever, weight loss, and lung cavities visible on chest X-ray. The National Institutes of Health’s 2025 research review found that African American and Filipino individuals have a 3-5 times higher risk of disseminated disease compared to other populations. The University of California San Francisco’s 2025 treatment protocol corroborates this finding, noting that genetic factors affecting immune response to Coccidioides antigens explain this disparity.

How Is Valley Fever Diagnosed and Confirmed?

Diagnosis begins with a blood test detecting antibodies against Coccidioides fungus, specifically the immunodiffusion test for IgM and IgG antibodies. According to the American Thoracic Society’s 2025 clinical guidelines, the enzyme immunoassay (EIA) is the most commonly used initial test, with sensitivity of 75-90% and specificity of 95% when performed 2-4 weeks after symptom onset. The University of California San Francisco’s 2025 diagnostic protocol recommends chest X-ray or CT scan to identify characteristic findings: hilar lymphadenopathy, pulmonary nodules, or thin-walled cavities. For suspected disseminated disease, the CDC’s 2025 testing algorithm requires cerebrospinal fluid analysis for meningitis cases and tissue biopsy for bone or skin lesions. Polymerase chain reaction (PCR) testing, available through the Arizona Department of Health Services laboratory, can detect fungal DNA within 24 hours. The Infectious Diseases Society of America’s 2025 guidelines emphasize that early diagnosis reduces the risk of disseminated disease by 40% when treatment begins within 2 weeks of symptom onset.

What Are the Risk Factors for Developing Valley Fever Symptoms?

Risk Factor	Increased Risk	Source
Living in Arizona or California	10x higher than general US population	CDC 2025 surveillance data
African American ethnicity	3-5x risk of disseminated disease	NIH 2025 research review
Filipino ethnicity	3-5x risk of disseminated disease	NIH 2025 research review
Pregnancy (third trimester)	2-3x risk of severe disease	IDSA 2025 guidelines
Immunosuppression (HIV, organ transplant)	5-10x risk of disseminated disease	CDC 2025 MMWR
Diabetes mellitus	2x risk of chronic pulmonary disease	University of Arizona 2025 cohort study
Age over 60 years	2x risk of severe disease	Mayo Clinic 2025 review
Occupational exposure (construction, agriculture)	3x risk of infection	NIOSH 2025 report

According to the National Institute for Occupational Safety and Health’s 2025 report, construction workers, agricultural workers, and archaeologists in endemic areas face the highest occupational risk. The Arizona Department of Health Services’ 2025 surveillance data shows that Maricopa County (Phoenix area) accounts for 60% of all US valley fever cases, with 8,500 reported cases in 2025 alone. The University of Arizona’s 2025 cohort study adds that individuals with blood type B have a 1.5x higher risk of symptomatic infection compared to blood type O, a finding awaiting independent corroboration.

How Is Valley Fever Treated Based on Symptom Severity?

Mild valley fever cases in otherwise healthy individuals often resolve without antifungal treatment within 3-6 weeks. According to the Infectious Diseases Society of America’s 2025 treatment guidelines, antifungal therapy is recommended for: all immunocompromised patients, pregnant women in the third trimester, individuals with severe or persistent symptoms lasting more than 6 weeks, and anyone with disseminated disease. The first-line treatment is fluconazole 400-800 mg daily for 3-6 months for pulmonary disease, and 12 months or longer for disseminated disease. The University of California San Francisco’s 2025 treatment protocol reports that itraconazole is preferred for bone and joint infections, while amphotericin B is reserved for severe, life-threatening cases. The Mayo Clinic’s 2025 outcomes study found that 95% of treated patients achieve symptom resolution within 12 months, but 10% experience relapse requiring extended therapy. The CDC’s 2025 surveillance data confirms that treatment adherence rates are highest (85%) among patients receiving nurse-led education programs.

What Is the Prognosis and Recovery Timeline for Valley Fever?

Recovery from valley fever follows a predictable timeline based on disease severity. According to the Mayo Clinic’s 2025 outcomes study, 70% of patients with mild disease recover fully within 3-6 weeks without antifungal treatment. For patients requiring fluconazole therapy, the University of California San Francisco’s 2025 treatment protocol reports that 80% achieve symptom resolution within 6 months, with the remaining 20% requiring 12 months or longer. The CDC’s 2025 surveillance data shows that 5% of patients develop chronic pulmonary cavities that persist for years, and 1% require surgical resection. The National Institutes of Health’s 2025 research review found that post-infection fatigue syndrome affects 15% of patients for 6-12 months after initial recovery, a finding corroborated by the University of Arizona’s 2025 cohort study.

What Are the Long-Term Complications of Valley Fever?

Long-term complications from valley fever develop in approximately 10% of symptomatic cases, according to the CDC’s 2025 Morbidity and Mortality Weekly Report. Chronic pulmonary coccidioidomycosis presents with persistent cough, hemoptysis (coughing blood), and lung cavities that can become superinfected with bacteria. The Infectious Diseases Society of America’s 2025 guidelines report that 2% of patients develop fibrocavitary disease, where lung tissue is replaced by scar tissue, reducing pulmonary function. Disseminated disease complications include coccidioidal meningitis, which has a 5% mortality rate even with treatment, according to the University of California San Francisco’s 2025 treatment protocol. The National Institutes of Health’s 2025 research review notes that joint destruction from coccidioidal arthritis occurs in 1% of disseminated cases, requiring orthopedic intervention.

How Can Valley Fever Be Prevented in Endemic Areas?

Prevention of valley fever focuses on reducing inhalation of Coccidioides spores in endemic areas. According to the CDC’s 2025 prevention guidelines, the most effective measures include: staying indoors during dust storms, wearing N95 respirators when outdoors in dusty conditions, wetting soil before digging or construction, and using HEPA filters in home HVAC systems. The National Institute for Occupational Safety and Health’s 2025 report recommends that employers in endemic areas provide N95 respirators and conduct workplace air monitoring for Coccidioides spores. The Arizona Department of Health Services’ 2025 surveillance data shows that construction sites using soil wetting protocols reduced worker infections by 60%. The University of Arizona’s 2025 cohort study found that pet owners who walk dogs in desert areas have a 2x higher risk of exposure, as dogs can carry spores on their fur.

What Should You Do If You Suspect Valley Fever Symptoms?

If you suspect valley fever symptoms, the Infectious Diseases Society of America’s 2025 guidelines recommend seeking medical evaluation within 7 days of symptom onset, especially if you have traveled to or live in Arizona, California’s Central Valley, New Mexico, Texas, or Nevada. The Mayo Clinic’s 2025 clinical review advises requesting a valley fever blood test (EIA for IgM and IgG antibodies) if you have pneumonia-like symptoms lasting more than 10 days without improvement. The CDC’s 2025 surveillance data shows that early diagnosis within 2 weeks of symptom onset reduces the risk of disseminated disease by 40%. The Arizona Department of Health Services’ 2025 annual report recommends that patients keep a symptom diary documenting fever patterns, cough characteristics, and rash development to aid diagnosis.

What Are the Latest Research Developments in Valley Fever Treatment?

Research into valley fever treatment has advanced significantly in 2025-2026. The National Institutes of Health’s 2025 research review highlights two promising developments: the antifungal agent olorofim, currently in Phase 3 clinical trials, which shows efficacy against fluconazole-resistant Coccidioides strains; and a vaccine candidate (Coccidioides delta-cps1) that completed Phase 1 trials in 2025 with 90% antibody response in healthy volunteers. The University of Arizona College of Medicine’s 2025 cohort study reports that a 2-week course of high-dose fluconazole (1200 mg daily) reduced symptom duration by 30% compared to standard dosing. The CDC’s 2025 surveillance data confirms that telemedicine-based valley fever management programs in rural Arizona improved treatment adherence by 25% compared to in-person care.